Bli medlem
Bli medlem

Du är här


DGAP-News: Abivax announces the success of its oversubscribed capital increase of EUR 28m at market price

DGAP-News: ABIVAX / Key word(s): Capital Increase
Abivax announces the success of its oversubscribed capital increase of EUR 28m at market price

29.10.2020 / 08:01
The issuer is solely responsible for the content of this announcement.

Abivax announces the success of its oversubscribed capital increase of EUR 28m at market price

  • Subscribed by top-tier U.S. and European biotech investors (12 investors in total, 55% of funds raised from European investors, 45% from the U.S.)
  • Total financing since June 2020 amounting to EUR 84m, 2/3 non-dilutive (EUR 56m from Bpifrance, Kreos, Société Générale) and 1/3 dilutive (EUR 28m capital raise)
  • Proceeds to be used for funding late-stage clinical testing of ABX464 in inflammatory diseases (ulcerative colitis, Crohn's disease and Covid-19
  • Cash for operations extended until Q4 2021

PARIS, FRANCE, October 29, 2020 - 7:30 a.m. (CET) - Abivax (Euronext Paris: FR0012333284 - ABVX) (the "Company"), a clinical-stage biotechnology company harnessing the immune system to develop novel treatments for inflammatory diseases, viral diseases and cancer, today announces the successful completion of a capital increase of EUR 28m, through the issuance of 1,620,370 new ordinary shares with a nominal value of EUR 0.01 each (the "New Shares"), representing 11.70% of its share capital after the capital increase (the "Capital Increase"), at a subscription price of EUR 17.28 per share (market price). Gross proceeds from the Capital Increase amount to EUR 27,999,993.60.

Reasons for the issuance and use of the proceeds

The gross proceeds from the transaction are EUR 27,999,993.60, which will be used, along with the recent non-dilutive financings, by the Company for:

  • completion of the Phase 2b induction phase, pursuance of the maintenance phase and preparation of Phase 3 of ABX464 in ulcerative colitis (UC);
  • completion of the Phase 2a induction phase and pursuance of the maintenance phase of ABX464 in rheumatoid arthritis (RA);
  • completion of Phase 2b/3 of ABX464 in COVID-19 indication and preparation for regulatory filings, market access and commercialization, if clinical data are positive;
  • preparation of Phase 2b/3 of ABX464 in Crohn's disease (CD); and
  • general corporate purposes.

The Company expects that the gross proceeds from the transaction will provide the Company with financial resources (cash runway) to fund its operations to Q4 2021, based on ongoing programs.

Prof. Hartmut J. Ehrlich, M.D., CEO of Abivax said: "We are very happy with the successful completion of Abivax's capital increase of EUR 28m which will contribute to achieve a number of important value-creating milestones. In particular, we are looking forward to a favorable data read-out of the Phase 2b clinical study with ABX464 in ulcerative colitis, planned for Q2 2021, which would further strengthen our position for potential partnering discussions. At the same time, Abivax is pursuing its clinical development of ABX464 with the completion of the Phase 2a study in rheumatoid arthritis and the preparation of a pivotal Phase 2b/3 study in Crohn's disease. In addition, enrollment in the Covid-19 trial with ABX464 is progressing well and, depending on the evolution of the pandemic, we are planning to have first top-line results in Q1 2021. We are very much looking forward to bringing these exciting, highly differentiated novel treatments with ABX464 to patients in need."

Didier Blondel, CFO of Abivax, added: "Given the current market conditions, the capital increase of EUR 28m is a great success for the Company as well as for our existing shareholders as it was oversubscribed at market price with a limited dilution of 11.70%. In addition to our recent non-dilutive financings, it extends our cash runway until Q4 2021. We will make efficient and targeted use of these financial resources to accomplish our corporate goals and create value for our shareholders."

Key characteristics of the Capital Increase

The New Shares are being issued through a capital increase without shareholders' preferential subscription right reserved to a specified category of investors pursuant to the provisions of Article L. 225-138 of the French Commercial Code and to the 15th resolution of the Annual General Shareholders' Meeting held on June 19, 2020. In accordance with such resolution, the subscription price per share must be at least equal to the weighted average by the volumes of the share prices over the fifteen (15) trading days preceding the date the issue price is set, it being specified that it may be reduced by a discount of at most 15%.

The number of ordinary shares subscribed and the subscription price were decided by the Company's Chief Executive Officer (Directeur Général), in accordance with a sub-delegation granted by the Company's Board of Directors on October 28, 2020. In accordance with the Board of Directors' internal rules, the representatives of Sofinnova and of Santé Holding did not participate in the deliberations of the Board of Directors relating to the Capital Increase.

The subscription price of the New Shares was set at EUR 17.28, i.e. with no discount to the last closing price (as of Wednesday October 28, 2020).

Two of the Company's existing large shareholders participated in the Capital Increase. Sofinnova, which held a 12.26% stake in the Company, subscribed to the Capital Increase for an amount of EUR 3.4m corresponding to 198,723 New Shares. After the Capital Increase, Sofinnova will continue to hold 12.26% of the share capital of the Company. Santé Holding, which held a 3.65% stake in the Company, subscribed in the Capital Increase for an amount of EUR 1m corresponding to 57,870 New Shares. After the Capital Increase, Santé Holding will hold 3.64% of the share capital of the Company.

The Funds of Truffle Capital (including Holding Incubatrice) remain the largest shareholder with 40.61%.

Besides Sofinnova and Santé Holding, ten other investors participated in the Capital Increase.

Payment and delivery of the New Shares is expected to occur on or around November 2, 2020 (the "Settlement Date"). As of the Settlement Date, the New Shares will be fungible with the Company's existing shares and will be entitled to current dividend rights.

The New Shares will be listed on Euronext Paris under ISIN FR0012333284 on November 2, 2020.

Bryan, Garnier & Co acted as Sole Global Coordinator and Sole Bookrunner for the Capital Increase.

Lock-up agreements

The Company has entered into a customary lock-up agreement, which provides for a 90-day standstill period on future share issuances. The Company's board members and observers (including Kreos Capital), and the officers who own shares or BSPCEs of the Company have also entered into customary lock-up agreements restricting disposals of the shares they currently own for the same period, in each case, subject to certain customary exceptions.

Impact of the Capital Increase on the share capital

Following settlement and delivery, the New Shares will represent 11.70% of the share capital of the Company and the Company's total share capital will be EUR 138,512.39 divided into 13,851,239 shares. For illustration purposes, a shareholder holding 1% of the Company's share capital prior to the Capital Increase, will hold 0.88% of the Company's share capital upon completion of the Capital Increase (or 0.75% on a fully diluted basis).

Allocation of the share capital following the Capital Increase

The issuance of the New Shares will have the following impact on the allocation of the share capital and the voting rights of the Company:

 Before TransactionAfter Transaction 
ShareholdersNumber of shares% capital (non-diluted)% capital (fully diluted)% voting rights (non-diluted)% voting rights (fully diluted)Number of shares% capital (non-diluted)% capital (fully diluted)% voting rights (non-diluted)% voting rights (fully diluted) 
Truffle Capital5 414 74544,27%37,00%58,20%51,15%5 414 74539,09%33,31%53,25%47,28% 
Holding Incubatrice210 9701,72%1,44%1,95%1,71%210 9701,52%1,30%1,78%1,58% 
Sofinnova1 500 00012,26%10,25%8,61%7,57%1 698 72312,26%10,45%8,92%7,92% 
Santé Holding446 0113,65%3,71%2,56%2,74%503 8813,64%3,70%2,65%2,80% 
Management and board of Directors (excl. Santé Holding & Sofinnova)505 0784,13%10,05%4,19%8,55%505 0783,65%9,05%3,83%7,90% 
Other (1)164 7941,35%5,85%1,59%4,88%164 7941,19%5,26%1,46%4,51% 
Free float
Författare ABIVAX

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.